AstraZeneca is one of the largest companies listed in London and Britain's biggest pharmaceutical group. Over the past decade it's reshaped itself around oncology, cardiovascular-renal-metabolic disease, respiratory and immunology, and rare diseases, with a public ambition to reach $80bn of annual revenue by 2030. Scale brings scrutiny though: a deep late-stage pipeline has to actually convert into approvals.

The Quick Version

  • AstraZeneca reported full-year 2025 total revenue of $58,739m, up 9% (8% at constant currency), and reaffirmed its $80bn-by-2030 ambition.
  • Oncology is the largest engine, generating $25.6bn in 2025, led by Tagrisso, Imfinzi, Calquence and Enhertu.
  • The pipeline saw both wins and setbacks in 2026: baxdrostat (Baxfendy) won US approval in hypertension, while camizestrant met a mixed US regulatory reception despite a positive EU opinion.
  • The company retains its LSE primary listing and FTSE 100 membership; it added a direct NYSE listing in February 2026.
  • Clinical development, pricing pressure, US policy and patent expiries remain material uncertainties.

An Oncology-Led Commercial Engine

AstraZeneca is headquartered in Cambridge, organised around four therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology, and Rare Disease (built substantially on the 2021 Alexion acquisition). It's a FTSE 100 constituent under ticker AZN, with primary listing in London plus Nasdaq Stockholm; in February 2026 it added a direct NYSE listing, replacing its previous Nasdaq ADS line, while stating London and Stockholm listings and index memberships were unaffected.

In 2025, oncology generated $25,619m of revenue, up 15%, roughly 44% of the group total — anchored by Tagrisso ($7,254m), Imfinzi ($6,063m, up 29%), Calquence ($3,518m) and Enhertu ($2,775m, up 40%). The company now has 16 medicines each generating more than $1bn in annual sales.

A Win: Baxdrostat's US Approval

Baxdrostat, an oral aldosterone synthase inhibitor for hard-to-control blood pressure, was approved in the US on 18 May 2026 under the brand Baxfendy — described by the company as the first and only medicine of its class for hypertension, potentially opening a large cardiovascular market.

A Setback: Camizestrant's Mixed US Reception

Camizestrant, by contrast, met a more cautious US reception: an FDA Oncologic Drugs Advisory Committee in April 2026 did not reach a majority in favour of the SERENA-6 switching strategy for HR-positive, HER2-negative advanced breast cancer, prompting an extension of the US decision date, even as European regulators issued a positive opinion in May 2026 — a reminder that positive data in one region doesn't guarantee approval in another.

The Push Into Obesity

In June 2026 the company said it would advance elecoglipron, an oral small-molecule GLP-1 receptor agonist, into a Phase III programme spanning obesity and type 2 diabetes — the clearest step yet into the fast-growing weight-management field, complemented by a CSPC Pharmaceuticals collaboration. That market is already served by established incumbents, so elecoglipron's commercial relevance hinges on Phase III data not yet available.

The Financial Picture

Reported EPS rose 45% to $6.60 in 2025, while core EPS increased 12% to $9.16. R&D spending reached $14,232m, about 24% of revenue. Net debt stood at $23,374m, down roughly $1.2bn over the year. The board declared a full-year 2025 dividend of $3.20 per share and intends to raise it to $3.30 for 2026. Q1 2026 revenue was $15,288m, up 13% (8% CER), with core EPS of $2.58, and guidance reconfirmed. For 2026, the company guides to mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant currency.

In July 2025 the company announced plans to invest $50bn in the US in manufacturing and R&D through 2030, including an expanded Virginia facility — a move widely read against US tariff and drug-pricing policy debates.

Risks Worth Weighing

Clinical and regulatory uncertainty is intrinsic — as camizestrant showed, late-stage assets can encounter setbacks in one region even after success elsewhere. Patent expiries on major earners could erode revenue if newer products don't ramp quickly enough. Drug-pricing policy, particularly in the US, remains a live source of uncertainty, alongside potential tariffs affecting cross-border manufacturing. Currency translation, execution risk on the sizeable US investment programme, and competition in crowded fields such as obesity round out the picture.

What to Watch Next

A US regulatory decision on camizestrant following the extended review. Phase III readouts for elecoglipron in obesity and type 2 diabetes. Further indication expansions for Enhertu, Datroway and Imfinzi, and the commercial trajectory of newly approved Baxfendy. Progress against the 2030 revenue ambition at each quarterly update.